Human iPSC and CRISPR targeted gene knock-in strategy for studying the somatic TIE2L914F mutation in endothelial cells
Angiogenesis · 2024-08 · 27 (3) · 523-542
DOI: 10.1007/s10456-024-09925-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angiogenesis, online erschienen am 21.05.2024. Verfasst von Bojana Lazovic und 18 weiteren Autor:innen. Beteiligte Einrichtung: BioPharmaceuticals R&D Cell Therapy Department, Research and Early Development, Cardiovascular, Renal, and Metabolism (CVRM), BioPharmaceuticals R&D,…. Hauptthemen laut MEDLINE: Induced Pluripotent Stem Cells, Receptor, TIE-2, Endothelial Cells, Gene Knock-In Techniques. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement, European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement.
Abstract (Originalsprache)
Induced pluripotent stem cell (iPSC) derived endothelial cells (iECs) have emerged as a promising tool for studying vascular biology and providing a platform for modelling various vascular diseases, including those with genetic origins. Currently, primary ECs are the main source for disease modelling in this field. However, they are difficult to edit and have a limited lifespan. To study the effects of targeted mutations on an endogenous level, we generated and characterized an iPSC derived model for venous malformations (VMs). CRISPR-Cas9 technology was used to generate a novel human iPSC line with an amino acid substitution L914F in the TIE2 receptor, known to cause VMs. This enabled us to study the differential effects of VM causative mutations in iECs in multiple in vitro models and assess their ability to form vessels in vivo. The analysis of TIE2 expression levels in TIE2 L914F iECs showed a significantly lower expression of TIE2 on mRNA and protein level, which has not been observed before due to a lack of models with endogenous edited TIE2 L914F and sparse patient data. Interestingly, the TIE2 pathway was still significantly upregulated and TIE2 showed high levels of phosphorylation. TIE2 L914F iECs exhibited dysregulated angiogenesis markers and upregulated migration capability, while proliferation was not affected. Under shear stress TIE2 L914F iECs showed reduced alignment in the flow direction and a larger cell area than TIE2 WT iECs. In summary, we developed a novel TIE2 L914F iPSC-derived iEC model and characterized it in multiple in vitro models. The model can be used in future work for drug screening for novel treatments for VMs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- BioPharmaceuticals R&D Cell Therapy Department, Research and Early Development, Cardiovascular, Renal, and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
- Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
- Oulu Center for Cell-Matrix Research, Biocenter Oulu and Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland.
- Finnadvance Ltd., Oulu, Finland.
- Data Sciences and Quantitative Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
- Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
Förderung
- European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement
- European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement
Zitieren
APA
Lazovic, B., Nguyen, H. T., Ansarizadeh, M., Wigge, L., Kohl, F., Li, S., Carracedo, M., Kettunen, J., Krimpenfort, L., Elgendy, R., Richter, K., De Silva, L., Bilican, B., Singh, P., Saxena, P., Jakobsson, L., Hong, X., Eklund, L., & Hicks, R. (2024). Human iPSC and CRISPR targeted gene knock-in strategy for studying the somatic TIE2L914F mutation in endothelial cells. Angiogenesis, 27(3), 523-542. https://doi.org/10.1007/s10456-024-09925-9
Vancouver
Lazovic B, Nguyen HT, Ansarizadeh M, Wigge L, Kohl F, Li S, et al. Human iPSC and CRISPR targeted gene knock-in strategy for studying the somatic TIE2L914F mutation in endothelial cells. Angiogenesis. 2024;27(3):523-542. doi:10.1007/s10456-024-09925-9
BibTeX
@article{Lazovic2024,
author = {Lazovic, Bojana and Nguyen, Hoang-Tuan and Ansarizadeh, Mohammadhassan and Wigge, Leif and Kohl, Franziska and Li, Songyuan and Carracedo, Miguel and Kettunen, Jere and Krimpenfort, Luc and Elgendy, Ramy and Richter, Kati and De Silva, Laknee and Bilican, Bilada and Singh, Prateek and Saxena, Pratik and Jakobsson, Lars and Hong, Xuechong and Eklund, Lauri and Hicks, Ryan},
title = {Human iPSC and CRISPR targeted gene knock-in strategy for studying the somatic TIE2L914F mutation in endothelial cells},
journal = {Angiogenesis},
year = {2024},
volume = {27},
number = {3},
pages = {523--542},
doi = {10.1007/s10456-024-09925-9}
}
EUVIMED